Table 4.
Results of regression analysis of clinical outcomes of COVID-19 in hematological patients following PSM.
| Clinical and Laboratory Parameters | 30-Day Mortality AOR (95% CI) |
Hospitalization for Intensive Cure AOR (95% CI) |
14-Day Viral Clearance AOR (95% CI) |
|---|---|---|---|
| Age >70 years | 0.01 (−0.49–0.51) |
−0.11 (−0.49–0.26) |
0.1 (−0.26–0.48) |
| Sex: female | −0.01 (−0.44–0.42) |
−0.16 (−0.49–0.17) |
0.11 (0.21–0.43) |
| Not active and progressing disease | −0.64 (−1.09–0.2) |
−0.12 (−0.44–0.20) |
0.13 (0.19–0.45) |
| Charlson comorbidity index 0 | −0.39 (−1.02–0.23) |
−0.36 (−0.88–0.14) |
0.38 (−0.12–0.89) |
| Lymphoid neoplasm | 0.08 (−0.39–0.55) |
0.037 (−0.30–0.38) |
0.16 (−0.19–0.52) |
| Myeloid neoplasm | −0.18 (−0.7–0.34) |
−0.11 (−0.49–0.26) |
0.19 (−0.18–0.56) |
| Plasma cell neoplasm | 0 (−0.42–0.28) |
0 (−0.42–0.36) |
0 (−0.42–0.34) |
| LDH > 243 IU/L | −0.0008 (−0.45–0.45) |
−0.07 (−0.42–0.28) |
0.32 (−0.04–0.67) |
| C-RP > 5 IU/L | −0.03 (−0.42–0.36) |
−0.27 (0.57–0.03) |
0.04 (−0.27–0.35) |
| AMC < 0.4 × 103 cells/uL | 0.68 (0.14–1.21) |
0.17 (−0.14–0.49) |
0 (−0.31–0.31) |
Abbreviations: LDH, lactate de-hydrogenase; C-RP, C-reactive protein; AMC, absolute monocyte count, uL, microliter, IU/L, international units per liter.